AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39413050 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-oxidized solution
Number of subjects: 102
Study 39413050 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 102
Study 39413203 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39413305 — intervention group
Group type: EXPERIMENTAL
Intervention: PriCARE intervention (n = 92)
Number of subjects: 182
Study 39413305 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n = 90)
Number of subjects: 182
Study 39413339 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 70
Study 39413359 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR(BC)) program
Number of subjects: 0
Study 39413375 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD)
Number of subjects: 970
Study 39413375 — intervention group
Group type: COMPARATOR
Intervention: Brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (BV+AVD)
Number of subjects: 970
Study 39413376 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation from donors with HIV
Number of subjects: 408
Study 39413376 — intervention group
Group type: COMPARATOR
Intervention: Kidney transplantation from donors without HIV
Number of subjects: 408
Study 39413377 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT (36.25 Gy in 5 fractions over 1 or 2 weeks)
Number of subjects: 874
Study 39413377 — intervention group
Group type: COMPARATOR
Intervention: Control radiotherapy (78 Gy in 39 fractions over 7.5 weeks or 62 Gy in 20 fractions over 4 weeks)
Number of subjects: 874
Study 39413377 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT
Number of subjects: 874
Study 39413377 — intervention group
Group type: COMPARATOR
Intervention: Control radiotherapy
Number of subjects: 874
Study 39413735 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m²) plus toripalimab
Number of subjects: 0
Study 39413989 — intervention group
Group type: COMPARATOR
Intervention: Online recruitment strategies
Number of subjects: 649
Study 39413989 — intervention group
Group type: COMPARATOR
Intervention: Traditional recruitment strategies
Number of subjects: 649
Study 39413989 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment effectiveness
Number of subjects: 649
Study 39413989 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for ineligibility
Number of subjects: 649
Study 39413990 — intervention group
Group type: EXPERIMENTAL
Intervention: CS + Fast (110 kcal of sucrose)
Number of subjects: 64
Study 39413990 — intervention group
Group type: EXPERIMENTAL
Intervention: CS + Slow (110 kcal of maltodextrin)
Number of subjects: 64
Study 39413990 — intervention group
Group type: COMPARATOR
Intervention: CS- (0-kcal sucralose)
Number of subjects: 64
Study 39414121 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported outcomes
Number of subjects: 110
Study 39414121 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent communication strategies
Number of subjects: 110
Study 39414121 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent and child self-report
Number of subjects: 110
Study 39414223 — intervention group
Group type: COMPARATOR
Intervention: Fortified eggs (FE) - instructed to consume at least 12 FE/week; Control: nonegg supplemented diet - restricted to <2 eggs/week
Number of subjects: 140
Study 39414223 — intervention group
Group type: COMPARATOR
Intervention: Time-restricted eating (TRE) - instructed to consume all calories within an 8-hour window; Control: usual care diet - advised to maintain current dietary habits
Number of subjects: 140
Study 39414268 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-delivered behavioural activation (I-BA) for 10 weeks
Number of subjects: 215
Study 39414268 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided internet-delivered behavioural activation (I-BA) for 10 weeks
Number of subjects: 215
Study 39414268 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) provided by regular mental health clinics
Number of subjects: 215
Study 39414268 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (therapist-guided I-BA, self-guided I-BA, TAU)
Number of subjects: 215
Study 39414276 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised treatment including LLN dissection (LLND) after neoadjuvant treatment and TME surgery.
Number of subjects: 200
Study 39414276 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment by trained radiation oncologists followed by TME surgery.
Number of subjects: 200
Study 39414276 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised treatment including LLND.
Number of subjects: 200
Study 39414278 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy school lunch provided for 18 weeks
Number of subjects: 5
Study 39414278 — intervention group
Group type: COMPARATOR
Intervention: Children bringing their own lunch from home
Number of subjects: 5
Study 39414279 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) including omeprazole, esomeprazole, and pantoprazole
Number of subjects: 1264798
Study 39414279 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 1264798
Study 39414282 — intervention group
Group type: EXPERIMENTAL
Intervention: Rock-climbers
Number of subjects: 363
Study 39414282 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 363
Study 39414286 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum telephone support for lifestyle changes
Number of subjects: 466
Study 39414286 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 466
Study 39414294 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load strength training (2 weekly sessions for 12 weeks)
Number of subjects: 100
Study 39414294 — intervention group
Group type: COMPARATOR
Intervention: Standard care (low-intensity strength training and/or proprioceptive training)
Number of subjects: 100
Study 39414298 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Repetitive Arm Supplementary Programme (GRASP) combined with Post-Rehabilitation Enablement Programme (PREP) for 6 weeks
Number of subjects: 72
Study 39414298 — intervention group
Group type: COMPARATOR
Intervention: Post-Rehabilitation Enablement Programme (PREP) for 6 weeks
Number of subjects: 72
Study 39414325 — intervention group
Group type: EXPERIMENTAL
Intervention: NG-350A (intravenous administration)
Number of subjects: 25
Study 39414325 — intervention group
Group type: EXPERIMENTAL
Intervention: NG-350A (intratumoral administration)
Number of subjects: 25
Study 39414341 — intervention group
Group type: EXPERIMENTAL
Intervention: Videogame application for 8 weeks
Number of subjects: 28
Study 39414341 — intervention group
Group type: COMPARATOR
Intervention: Weekly WhatsApp messages on healthy behaviours (Control)
Number of subjects: 28
Study 39414374 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard audit and feedback (AF) and educational summary (ES) intervention arm (n=1691)
Number of subjects: 5073
Study 39414374 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational summary (ES)-only arm (n=1691)
Number of subjects: 5073
Study 39414374 — intervention group
Group type: COMPARATOR
Intervention: Control arm (n=1691)
Number of subjects: 5073
Study 39414418 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly efanesoctocog alfa prophylaxis 50 IU/kg for 52 weeks (Arm A)
Number of subjects: 159
Study 39414418 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand efanesoctocog alfa 50 IU/kg for 26 weeks followed by 26 weeks once-weekly prophylaxis (50 IU/kg; Arm B)
Number of subjects: 159
Study 39414418 — intervention group
Group type: EXPERIMENTAL
Intervention: Efanesoctocog alfa prophylaxis
Number of subjects: 159
Study 39414418 — intervention group
Group type: COMPARATOR
Intervention: Pre-study treatment
Number of subjects: 159
Study 39414623 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-scout intervention
Number of subjects: 472
Study 39414623 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 472
Study 39414987 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-42165279 (25 mg, twice-daily)
Number of subjects: 61
Study 39414987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 39414998 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in sedentary behavior by 1 hour/day
Number of subjects: 64
Study 39414998 — intervention group
Group type: COMPARATOR
Intervention: Control group maintaining usual sedentary behavior habits
Number of subjects: 64
Study 39414999 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital mindset intervention focusing on adaptive mindsets
Number of subjects: 408
Study 39414999 — intervention group
Group type: COMPARATOR
Intervention: No-intervention group
Number of subjects: 408
Study 39414999 — intervention group
Group type: COMPARATOR
Intervention: Digital education intervention
Number of subjects: 408
Study 39415093 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in mental health services
Number of subjects: 20
Study 39415117 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical and Social Functioning scale (PSF)
Number of subjects: 562
Study 39415149 — intervention group
Group type: EXPERIMENTAL
Intervention: High IPAQ category (n=137)
Number of subjects: 1270
Study 39415149 — intervention group
Group type: COMPARATOR
Intervention: Moderate IPAQ category (n=995)
Number of subjects: 1270
Study 39415149 — intervention group
Group type: COMPARATOR
Intervention: Low IPAQ category (n=138)
Number of subjects: 1270
Study 39415181 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 51
Study 39415182 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy (ABFT)
Number of subjects: 142
Study 39415182 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 142
Study 39415279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinetrol
Number of subjects: 0
Study 39415283 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week structured physical activity programme supervised by a sport medicine physician, preceded by three psychoeducation sessions on healthy eating habits.
Number of subjects: 64
Study 39415283 — intervention group
Group type: COMPARATOR
Intervention: 12-week psychoeducation programme on physical activity, diet, and health risks of a sedentary lifestyle for a total of 8 sessions.
Number of subjects: 64
Study 39415282 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative immunonutrition (IN) for 7 days
Number of subjects: 232
Study 39415282 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 232
Study 39415344 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotiglipron 80 mg
Number of subjects: 901
Study 39415344 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotiglipron 200 mg (five-step titration)
Number of subjects: 901
Study 39415344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 901
Study 39415344 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotiglipron (T2D cohort)
Number of subjects: 901
Study 39415507 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation with lapatinib
Number of subjects: 681
Study 39415507 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemoradiation without lapatinib
Number of subjects: 681
Study 39415507 — intervention group
Group type: EXPERIMENTAL
Intervention: High NLR
Number of subjects: 681
Study 39415507 — intervention group
Group type: EXPERIMENTAL
Intervention: High ANC
Number of subjects: 681
Study 39415507 — intervention group
Group type: EXPERIMENTAL
Intervention: High ALC
Number of subjects: 681
Study 39415599 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 146
Study 39415599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 39415650 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole (2–3 mg/day)
Number of subjects: 489
Study 39415650 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive placebo (brexpiprazole withdrawal)
Number of subjects: 489
Study 39415796 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented reality (AR)-based telerehabilitation system
Number of subjects: 56
Study 39415796 — intervention group
Group type: COMPARATOR
Intervention: Brochure-based rehabilitation program
Number of subjects: 56
Study 39415799 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention (Veteran peer Coaches Optimizing and Advancing Cardiac Health)
Number of subjects: 29
Study 39415882 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra soft cushioning material at the rear part of the shoe
Number of subjects: 1000
Study 39415882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushioning under the forepart of the shoe
Number of subjects: 1000
Study 39415900 — intervention group
Group type: EXPERIMENTAL
Intervention: MP0250 in combination with bortezomib and dexamethasone
Number of subjects: 33
Study 39415923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib monotherapy
Number of subjects: 773
Study 39415923 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy (AT-E)
Number of subjects: 773
Study 39415923 — intervention group
Group type: COMPARATOR
Intervention: No antithrombotic therapy
Number of subjects: 773
Study 39415930 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (VEN) at doses of 400, 600, or 800 mg combined with liposomal vincristine (L-VCR) at 2.25 mg/m weekly
Number of subjects: 18
Study 39415930 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of VEN and L-VCR
Number of subjects: 18
Study 39416174 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCT-701, a DLK1 targeting antibody-drug conjugate (ADC)
Number of subjects: 0
Study 39416927 — intervention group
Group type: EXPERIMENTAL
Intervention: Juggling intervention
Number of subjects: 20
Study 39416927 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 20
Study 39416950 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-dose dexmedetomidine (median 0.02 μg/kg/h)
Number of subjects: 152
Study 39416950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 39416990 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Influenza Vaccine (RIV)
Number of subjects: 3988
Study 39416990 — intervention group
Group type: COMPARATOR
Intervention: Standard-Dose Inactivated Influenza Vaccine (SD IIV)
Number of subjects: 3988
Study 39417106 — intervention group
Group type: EXPERIMENTAL
Intervention: DKN-01/nivolumab
Number of subjects: 0
Study 39417128 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole food, plant-based diet for 8 weeks
Number of subjects: 17
Study 39417152 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 2 mg mometasone irrigations for 2 months in an optimized position as determined by a patient-specific 3D printed irrigation model (MG)
Number of subjects: 62
Study 39417152 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 2 mg mometasone irrigations for 2 months with a head tilt of 90° to the side with fluid entering the lower nostril (BG)
Number of subjects: 62
Study 39417152 — intervention group
Group type: COMPARATOR
Intervention: Daily 2 mg mometasone irrigations for 2 months with standard head-forward and natural side-tilt position (CG)
Number of subjects: 62
Study 39417218 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10 2+1 schedule
Number of subjects: 0
Study 39417218 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 2+1 schedule
Number of subjects: 0
Study 39417218 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced 1+1 PCV dosing schedule
Number of subjects: 0
Study 39417384 — intervention group
Group type: EXPERIMENTAL
Intervention: Music and Sleep Hygiene (MSH)
Number of subjects: 98
Study 39417384 — intervention group
Group type: COMPARATOR
Intervention: Sleep Hygiene alone (SH)
Number of subjects: 98
Study 39418015 — intervention group
Group type: EXPERIMENTAL
Intervention: TPA
Number of subjects: 56
Study 39418015 — intervention group
Group type: COMPARATOR
Intervention: C3F8
Number of subjects: 56
Study 39418015 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined C3F8 and TPA
Number of subjects: 56
Study 39418015 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 56
Study 39418029 — intervention group
Group type: EXPERIMENTAL
Intervention: LEN-IE (lenvatinib 14 mg/m2 orally once daily + ifosfamide 3000 mg/m2 IV + etoposide 100 mg/m2 IV on days 1-3 of each cycle)
Number of subjects: 81
Study 39418029 — intervention group
Group type: COMPARATOR
Intervention: IE (ifosfamide 3000 mg/m2 IV + etoposide 100 mg/m2 IV on days 1-3 of each cycle)
Number of subjects: 81
Study 39418029 — intervention group
Group type: EXPERIMENTAL
Intervention: LEN-IE
Number of subjects: 81
Study 39418029 — intervention group
Group type: COMPARATOR
Intervention: IE
Number of subjects: 81
Study 39418096 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotely delivered exercise intervention group (12-week personalized avatar-guided home exercise program)
Number of subjects: 40
Study 39418096 — intervention group
Group type: COMPARATOR
Intervention: Control group (electronic health diary)
Number of subjects: 40
Study 39418210 — intervention group
Group type: EXPERIMENTAL
Intervention: MALS
Number of subjects: 210
Study 39418210 — intervention group
Group type: EXPERIMENTAL
Intervention: immunoparalysis
Number of subjects: 210
Study 39418242 — intervention group
Group type: EXPERIMENTAL
Intervention: In-phase bilateral upper limb exercises (30-60 minutes/session, 3 sessions/week for 12 weeks)
Number of subjects: 5
Study 39418242 — intervention group
Group type: EXPERIMENTAL
Intervention: In-phase bilateral upper limb exercises
Number of subjects: 5
Study 39418289 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular markers correlated against standard of care MRI-targeted histology and oncological outcomes.
Number of subjects: 60
Study 39418289 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular index derived from baseline (MolBL) and one year (MolFU) molecular profiles.
Number of subjects: 60
Study 39418289 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiological progression defined as a PRECISE score of 4 or 5.
Number of subjects: 60
Study 39418340 — intervention group
Group type: EXPERIMENTAL
Intervention: Socazolimab (5 mg/kg) and nab-paclitaxel (260 mg/m2) Q3w
Number of subjects: 20
Study 39418346 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus an aromatase inhibitor (AI)
Number of subjects: 469
Study 39418346 — intervention group
Group type: COMPARATOR
Intervention: Aromatase inhibitor (AI) alone
Number of subjects: 469
Study 39418437 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent proxy report
Number of subjects: 0
Study 39418437 — intervention group
Group type: COMPARATOR
Intervention: Child self-report
Number of subjects: 0
Study 39418443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness strategy coping messages
Number of subjects: 0
Study 39418443 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction strategy coping messages
Number of subjects: 0
Study 39418443 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39418460 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) therapy
Number of subjects: 130
Study 39418460 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) therapy plus sertraline
Number of subjects: 130
Study 39418626 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 131
Study 39418644 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351 plus venetoclax (CPX-351 30 units/m2: daunorubicin 13.2 mg/m2 and cytarabine 30 mg/m2; venetoclax 400 mg)
Number of subjects: 35
Study 39418644 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351 plus venetoclax
Number of subjects: 35
Study 39418669 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone monoester supplementation
Number of subjects: 40
Study 39418669 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 39418824 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender oil
Number of subjects: 60
Study 39418824 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint oil
Number of subjects: 60
Study 39418824 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 39418854 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 108
Study 39418854 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 108
Study 39418883 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (T)
Number of subjects: 6281
Study 39418883 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib + Trastuzumab (L + T)
Number of subjects: 6281
Study 39418883 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab followed by Lapatinib (T→L)
Number of subjects: 6281
Study 39418916 — intervention group
Group type: COMPARATOR
Intervention: 25% isocaloric-restricted diets (Control diet)
Number of subjects: 253
Study 39418916 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% isocaloric-restricted diets (Traditional Jiangnan diet)
Number of subjects: 253
Study 39418916 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% isocaloric-restricted diets (Mediterranean diet)
Number of subjects: 253
Study 39418986 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 633
Study 39418986 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 633
Study 39419035 — intervention group
Group type: EXPERIMENTAL
Intervention: rezvilutamide plus ADT
Number of subjects: 654
Study 39419054 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with chemoradiotherapy
Number of subjects: 500
Study 39419054 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy alone
Number of subjects: 500
Study 39419061 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with three cycles of intravenous paclitaxel (200 mg/m2) followed by adjuvant treatment.
Number of subjects: 46
Study 39419061 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with three cycles of intravenous paclitaxel (200 mg/m2).
Number of subjects: 46